Stem Cell Therapy Explained for International Patients

Stem cell therapy is a category of treatments rather than one standard procedure. In our regenerative medicine programme it means a preparation of living cells, given by a route chosen for your case, alongside the care you already receive.

The cells we work with most are mesenchymal stromal cells, usually shortened to MSCs, including cells taken from donated umbilical cord tissue. They are still widely called mesenchymal stem cells; the stromal name is now preferred, because in the body these cells have not been shown to behave as true stem cells. What they are studied for is something else, and it is the subject of the next section. Our umbilical cord MSC therapy guide describes that material in more detail.

Cells talk to the cells around them. They release soluble factors and tiny particles that carry biological messages, and neighbouring cells respond to those messages. Researchers call this paracrine signalling, and the particles extracellular vesicles. It is the main reason MSCs are studied in regenerative medicine.

Two lines of that research come up most often in the conditions we are asked about. The first is how these signals may influence the way the immune system and the inflammatory response behave, known as immunomodulation. The second is how they may interact with the tissue environment around an injury, including the signals that support local repair and blood supply.

This is a description of what treatment aims to influence, not a promise of what it will achieve. For most of the conditions patients ask us about, cell therapy is still being investigated rather than settled, and responses differ between people. We plan around that honestly: goals first, measured afterwards. The science guide to how stem cells work goes a step further into the biology, and stem cells compared with exosomes explains where cell-free products differ.

A treatment name on its own says very little. These five details are what make one plan different from another, and our medical team sets each of them against your diagnosis, your imaging and laboratory results, the medicines you take and the goals you want to work towards. You receive them in writing before anything is booked.

A more invasive route is not a stronger treatment. Each one reaches different tissue and carries its own procedural considerations, so the route follows the target and your safety. Your plan names the route, the setting, the clinician responsible, the monitoring during and after the procedure, and what we do if a complication occurs.

Suitability is decided by review, not by a condition appearing on a website. Our medical team looks for a confirmed diagnosis supported by recent records, a clear picture of the treatment you already receive, and goals that can be followed over time. We also assess contraindications, medication interactions and whether you are well enough for both the procedure and international travel.

Some findings mean we do not proceed, including active infection, a relevant cancer history, pregnancy and certain immune conditions, until a clinician has assessed them. If the review shows that treatment is not appropriate for your case, we tell you that rather than offering a plan anyway. Our safety and process guide sets out how material is handled and what is checked before use.

Some cell therapies are long-established: blood-forming stem cell transplantation is routine care for selected blood disorders. Much of the work with mesenchymal stromal cells is younger, and the strength of the evidence differs by condition, by product and by delivery route. We would rather you hear that from us than discover it later.

Regenerative medicine treatments are planned individually. Responses vary and no clinical outcome can be guaranteed. Suitability is confirmed only after medical review, and treatment is planned alongside your existing care, not in place of it. Nothing here asks you to change or stop a treatment your own clinician has prescribed.